These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 15298014)

  • 21. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmaceutical trademarks: navigating through the FDA's pilot program.
    Ferrer E
    Drug News Perspect; 2010 Jun; 23(5):333-6. PubMed ID: 20603657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical risk management: special problems encountered in the hospital setting.
    Benjamin DM
    J Healthc Risk Manag; 1998; 18(1):3-15. PubMed ID: 10176548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical risk management: special problems encountered in the hospital setting.
    Benjamin DM
    J Healthc Risk Manag; 1998; 18(2):5-17. PubMed ID: 10185078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reach-through claims for drug target patents: Rx for pharmaceutical policy.
    Bohrer RA
    Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015
    [No Abstract]   [Full Text] [Related]  

  • 26. The need for balancing the regulation of pharmaceutical trademarks between the Food and Drug Administration and the Patent and Trademark Office.
    Boring D; Doninger C
    Food Drug Law J; 1997; 52(1):109-16. PubMed ID: 10346714
    [No Abstract]   [Full Text] [Related]  

  • 27. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM
    Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
    [No Abstract]   [Full Text] [Related]  

  • 28. Can the safe harbor of 35 U.S.C. section 271(e)(1) shelter pioneer drug manufacturers?
    Brinckerhoff CC
    Food Drug Law J; 1998; 53(4):643-59. PubMed ID: 10557582
    [No Abstract]   [Full Text] [Related]  

  • 29. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 30. Indirect infringement.
    Becker DM
    Nat Rev Drug Discov; 2006 Mar; 5(3):181. PubMed ID: 16557655
    [No Abstract]   [Full Text] [Related]  

  • 31. India's IP snub.
    Jayaraman KS
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
    [No Abstract]   [Full Text] [Related]  

  • 32. The challenge to patent law of pure chemical protein synthesis.
    Fellmeth AX
    Nat Biotechnol; 2005 May; 23(5):547-9. PubMed ID: 15877067
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent developments in pharmaceutical products liability law: failure to warn, the learned intermediary defense, and other issues in the new millennium.
    Garbutt BJ; Hofmann ME
    Food Drug Law J; 2003; 58(2):269-86. PubMed ID: 12866558
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 36. U.S. patent law. Case probes what's fair game in the search for new drugs.
    Kintisch E
    Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
    [No Abstract]   [Full Text] [Related]  

  • 37. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 38. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
    O'Reilly JT
    Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
    [No Abstract]   [Full Text] [Related]  

  • 39. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 40. How Cuozzo will impact the interplay between post grant proceedings and Hatch-Waxman litigation.
    Mishra N; Doody PA; Davé RS
    Pharm Pat Anal; 2017 Jan; 6(1):9-15. PubMed ID: 28181455
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.